Phase 1Completed
Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects
Phase 1, Open-Label, Parallel Group Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP2C19 Inhibitor), Itraconazole (CYP3A4 Inhibitor) and Paroxetine (CYP2D6 Inhibitor) on the Pharmacokinetics of ASN51 in Healthy Subjects
- Sponsor
- Asceneuron S.A. (Industry)
- Enrollment
- 50 enrolled
- Conditions
- Drug Drug Interaction
- Interventions
- Fluvoxamine; Itraconazole; Paroxetine; ASN51
- Ages
- adults
- Registry
- NCT06232109
Full record on ClinicalTrials.gov
From the registry
The drug-drug interaction study has been designed to investigate the effect of Fluvoxamine, Itraconazole and Paroxetine on the pharmacokinetics of ASN51
Primary outcomes
- Cmax of ASN51
- Tmax of ASN51
- AUC0-tau of ASN51
- AUC0-inf of ASN51
History
Last registry update
Primary completion
Started
Registered